AbCellera Biologics (ABCL) Cash & Equivalents (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Cash & Equivalents data on file, last reported at $77.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 87.27% year-over-year to $77.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.1 million (down 87.27% YoY) and the FY2025 annual result came in at $128.5 million, up 340.11% from the prior year.
• Cash & Equivalents retreated to $77.1 million in Q1 2026, from $128.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.0 billion in Q2 2022 to a low of $5.8 million in Q4 2023.
• A 5-year average of $418.1 million and a median of $397.0 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 99.35% — and 2024, when it jumped 403.45%.
• Tracing ABCL's Cash & Equivalents over 5 years: stood at $886.5 million in 2022, then plunged by 99.35% to $5.8 million in 2023, then jumped by 403.45% to $29.2 million in 2024, then soared by 340.11% to $128.5 million in 2025, then tumbled by 40.03% to $77.1 million in 2026.
• The last three Cash & Equivalents figures came in at $77.1 million (Q1 2026), $128.5 million (Q4 2025), and $495.7 million (Q3 2025), per Business Quant data.